Becton Dickinson (BDX) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Becton Dickinson (NYSE:BDX) from a hold rating to a buy rating in a report issued on Wednesday morning.

Several other analysts also recently weighed in on BDX. Deutsche Bank set a $260.00 price target on shares of Becton Dickinson and gave the company a buy rating in a research note on Friday, December 29th. Evercore ISI started coverage on shares of Becton Dickinson in a research note on Wednesday, January 3rd. They set an outperform rating and a $245.00 price target for the company. Zacks Investment Research raised shares of Becton Dickinson from a hold rating to a buy rating and set a $240.00 price target for the company in a research note on Wednesday, January 3rd. KeyCorp started coverage on shares of Becton Dickinson in a research note on Friday, January 5th. They set an overweight rating and a $260.00 price target for the company. Finally, Citigroup raised shares of Becton Dickinson from a sell rating to a neutral rating in a research note on Friday, January 5th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Becton Dickinson presently has an average rating of Buy and a consensus price target of $241.19.

How to Become a New Pot Stock Millionaire

Becton Dickinson stock opened at $232.88 on Wednesday. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson has a fifty-two week low of $175.66 and a fifty-two week high of $248.39. The company has a market cap of $62,630.89, a PE ratio of 24.57, a P/E/G ratio of 1.71 and a beta of 1.15.

Becton Dickinson (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the firm posted $2.33 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. sell-side analysts predict that Becton Dickinson will post 10.95 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 9th were issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.29%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson’s payout ratio is 31.65%.

In other Becton Dickinson news, Director Timothy M. Ring sold 176 shares of Becton Dickinson stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the transaction, the director now directly owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the transaction, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 281,108 shares of company stock worth $61,321,396. 1.00% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legacy Advisors LLC grew its holdings in Becton Dickinson by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the last quarter. Amica Retiree Medical Trust grew its holdings in Becton Dickinson by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the last quarter. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson in the fourth quarter worth $109,000. FTB Advisors Inc. grew its holdings in Becton Dickinson by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares during the last quarter. Finally, Advisors Preferred LLC purchased a new position in Becton Dickinson in the fourth quarter worth $126,000. 83.46% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Becton Dickinson (BDX) Rating Increased to Buy at ValuEngine” was posted by Macon Daily and is owned by of Macon Daily. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://macondaily.com/2018/04/22/becton-dickinson-bdx-rating-increased-to-buy-at-valuengine.html.

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Becton Dickinson (NYSE:BDX)

Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply